For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Expert commentary
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
Later primary Tesomet paper describes regulator audit of earlier tesofensine trial.
Reported findings. Earlier publication reported weight outcomes, but carries an expression of concern rather than a retraction.
Nonresponse. The notice does not formally replace the published weight results. Later combination outcomes cannot be assigned to tesofensine alone.
Harms. Later primary paper reports regulator findings of under-reported headache, migraine, stress and depression in the earlier trial.
Limits. Detailed audit statements are attributed to the later primary paper; original Lancet notice full text was inaccessible. Safety interpretation is materially weakened. Tesomet includes metoprolol; it is not tesofensine-only preparation.
Preparation: Original tesofensine trial publication and later Tesomet combination context; formulations are distinct. Route: oral
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
32 healthy overweight or moderately obese men; two-week randomized controlled trial with habitual food intake/activity instructions.
Reported findings. Reported1.8kg placebo-subtracted weight loss and greater satiety/fullness; fat oxidation and adjusted nighttime energy expenditure increased.
Nonresponse. Total24-hour energy expenditure did not increase significantly.
Harms. Adverse-event details unavailable in accessible original abstract/preview; this omission does not establish safety.
Limits. Short mechanistic trial cannot establish durable obesity benefit or cardiovascular/psychiatric safety. Original abstract references older efficacy literature; its opening comparative superiority claim is not this trial’s independent head-to-head outcome. No linked correction/retraction/concern in freshly retrieved EuropePMC core; bounded exact-DOI notice search found none, not comprehensive clearance. Publisher preview includes funding/COI; full subscription methods and AE tables were inaccessible. Same research/developer network as older trial; independent participants are not independent funding or author replication. Funding/conflicts are attributed to the acquiring reviewer’s original publisher-preview observation. Independent disclosure reread blocked by publisher identity redirect; retained indexed abstract does not contain these declarations.
Preparation: Tesofensine alone versus placebo; no metoprolol. Study preparation is not commercial-capsule quality validation. Route: Daily administration; physical delivery route not explicitly verified in reviewed abstract/publisher preview.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Human trial
Randomized trial of the triple monoamine reuptake inhibitor NS2330(tesofensine) in early Parkinson’s disease
261 early-Parkinson’s-disease participants; randomized double-blind14-week proof-of-concept trial.
Reported findings. Transient improvement in highest-exposure arm atweek6 was reported but not sustained.
Nonresponse. All three active arms lacked significant totalUPDRS benefit atweek14 versus placebo.
Harms. Constipation,insomnia and dry mouth were common; decreased body weight and elevated heart rate common in highest-exposure arm.
Limits. Neurological outcome trial does not establish long-term obesity efficacy. Weight reduction is reported alongside adverse events, not a prespecified obesity success rate. Fresh original indexed metadata has no linked lifecycle correction/concern; publisher full text inaccessible, comprehensive clearance not asserted. Funding/conflict statement cannot be inferred from affiliations or generic ResearchSupport indexing. Pooled weight reanalysis18356831 includes this trial and must not be counted as independent subjects.
Preparation: NS2330/tesofensine monotherapy versus placebo; participants were not receiving dopaminergic treatment. Route: Daily administration; delivery route not explicitly verified in accessible primary abstract.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Human trial
MEX-TESObesity original UMIN registry results
372 Mexican adults randomized; reported24-week follow-up,288completed; two centers.
Reported findings. Registry reports mean absolute weight reduction1.9kg placebo versus5.3kg and8.6kg active groups.
Nonresponse. Arm-specific formal nonresponse/weight-loss-threshold counts not posted in reviewed results;84 discontinued.
Harms. Registry reports242participants with at least oneAE,1198events and12AE-related discontinuations. Two severe events in active groups(tendon rupture/cholecystitis) judged unlikely related; judgment is attributed, not causal clearance.
Limits. Original registry-entered results are not independently peer-reviewed published outcomes. Registration years after anticipated2017start/reported2018last-follow-up limits prospective verification. Last-follow-up date appears shorter than a full24-week period from anticipated start; chronology unresolved. Results-posted date precedes registered/disclosure dates; these are registry fields, not independently verified posting history. The results-publication link is incomplete and journal-publication date blank despite Published flag. Bounded exact investigator/title/372 search did not identify an original journal report. Pooled AE counts include placebo and must not be called tesofensine-caused event rates. Arm-level safety detail and missing-data method unavailable. Trial sponsor/funder reports do not validate commercial capsules or regulatory approval.
Preparation: Registered tesofensine monotherapy versus placebo; no metoprolol. Specific formulation and background diet/activity not specified in reviewed registry outcomes. Route: Physical route not specified in original registry excerpt; do not infer.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.